Cardiac Science (NASDAQ:DFIB)
Historical Stock Chart
From Jul 2019 to Jul 2024
Distribution of Cardiac Science Powerheart(R) AEDs Begins to U.S.
Hospitals
IRVINE, Calif., Feb. 10 /PRNewswire-FirstCall/ -- Cardiac Science Inc.
(NASDAQ:DFIB) announced today that GE Healthcare, a division of General
Electric Company (NYSE:GE), has initiated marketing and distribution of Cardiac
Science's line of Powerheart(R)-branded automated external defibrillators
(AEDs) and fully-automatic in-hospital defibrillator-monitors (CRMs) to
hospitals in the United States and Canada.
GE's sub-acute hospital sales force has begun marketing Cardiac Science's new
Powerheart AED G3 PRO, Powerheart AED G3 and Powerheart CRM(TM) this week.
Cardiac Science will support the GE sales effort via its regional sales
specialists located in strategic North American locations.
In November, Cardiac Science announced that it had expanded its multi-year
strategic distribution agreement with GE Healthcare. GE is currently marketing
a private-labeled version of the Powerheart AED G3 PRO device under the
GE-brand name Responder(R) AED PRO outside the U.S. and Canada.
Brad Jergenson GE's General Manager, Clinical Systems Sales said, "AEDs are
clearly in demand within hospitals and are being used to treat patients in the
non-acute sections of the hospital. The Powerheart AED G3 PRO with its unique
features is designed specifically with physicians and nurses in mind. We also
believe that the Powerheart CRM, given its small size and unique capabilities
for automatic bedside monitoring and defibrillation, will provide our customers
with a strong alternative to traditional crash cart defibrillators."
About the Powerheart(R) AED G3 PRO
The G3 PRO is a technologically advanced AED designed for use by sophisticated
users of lifesaving equipment such as hospital personnel, medical professionals
and emergency medical technicians. The G3 PRO is unique in that it displays
the victim's heart rhythm on a built-in high resolution color electrocardiogram
(ECG) display and gives professional users the option of delivering
defibrillation shocks either semi-automatically or manually during the
emergency treatment of victims of sudden cardiac arrest. Other advanced
features include continuous cardiac monitoring capability via an ECG patient
cable, multiple rescue data storage, clear and comprehensive AED and CPR voice
prompts, infrared data transfer and optional rechargeable battery.
About the Powerheart(R) Cardiac Rhythm Module (CRM)
The CRM is a lightweight fully-featured external defibrillator that offers a
complete therapeutic monitoring package in a single device -- continuous
cardiac monitoring, synchronized cardioversion, non-invasive pacing as well as
manual, semi-automatic or fully-automatic defibrillation. Designed for use in
hospitals, the CRM can be used to monitor patients during transport, as an
emergency defibrillator or be prophylactically attached to an at-risk cardiac
patient. Once attached to the patient via its disposable electrode pads and
programmed, the CRM can operate without the need for human intervention. It
continuously monitors a patient's heart, detects the onset of life-threatening
arrhythmias and can automatically deliver defibrillation therapy to patients
suffering from Sudden Cardiac Arrest.
About Cardiac Science
Cardiac Science develops, manufactures and markets a complete line of
Powerheart(R) brand, automated public access defibrillators (AEDs), and offers
comprehensive AED/CPR training and AED program management services that
facilitate successful deployments. The company makes the Powerheart(R)
CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and
automatically treats hospitalized cardiac patients who suffer life-threatening
heart rhythms. Cardiac Science also manufactures its AED products on a private
label basis for other leading medical companies such as Nihon Kohden (Japan),
Quinton Cardiology Systems and GE Healthcare. For more information please
visit http://www.cardiacscience.com/ or call 1.949.797.3800.
This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. In addition, from time
to time the company, or its representatives, have made or may make forward
looking statements orally or in writing. The words "estimate," "potential,"
"intended," "expect," "anticipate," "believe," and similar expressions or words
are intended to identify forward looking statements. Such forward-looking
statements include, but are not limited to the achievement of future revenue
growth based on the expanded agreement with GE. Cardiac Science cautions that
these statements are subject to substantial risks and uncertainties and are
qualified by important factors that could cause actual results to differ
materially from those reflected by the forward-looking statements and should
not be relied upon by investors when making an investment decision.
Information on these and other factors is detailed in the Company's Form 10-K
for the year ending December 31, 2003, subsequent quarterly filings, and other
documents filed by the Company with the Securities and Exchange Commission.
Contact: Matt Clawson (Investors) Michael D. Gioffredi
Allen & Caron Inc Chief Marketing Officer
(949) 474-4300 Cardiac Science, Inc.
(949) 797-3800
DATASOURCE: Cardiac Science, Inc.
CONTACT: Investors, Matt Clawson of Allen & Caron Inc, +1-949-474-4300,
, for Cardiac Science, Inc.; or Michael D. Gioffredi, Chief
Marketing Officer of Cardiac Science, Inc., +1-949-797-3800,
Web site: http://www.cardiacscience.com/